XTL Biopharmaceuticals Ltd (XTLB)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

XTL Announces Receipt of Staff Delist Determination from Nasdaq

RAMAT GAN, ISRAEL, May 22, 2026 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form NT 20-F - Notification of inability to timely file Form 20-F

Washington Just Opened the Door to Psychedelic Medicine; This Microcap Already Has a Key

The war on mental illness may be entering its most dramatic turning point in a generation. On April 18, President Trump signed an Executive Order...

XTL Biopharmaceuticals (XTLB) acquisition of Psyga Bio targets psychedelic biotech growth

XTL Biopharmaceuticals (NASDAQ:XTLB) announced an acquisition of Psyga Bio, a move that could reposition the company within the emerging...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

XTL Biopharmaceuticals to Acquire Psyga Bio, Establishing a Leading Psychedelic Biotechnology Platform with Advanced Clinical Pipeline, Licensed GMP Manufacturing and Proprietary Psilocybin Technologies

Transaction Positions XTL at the Forefront of the Rapidly Expanding Global Psychedelic Therapeutics Market...

Form 3 - Initial statement of beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

XTL Biopharmaceuticals Announces ADS Ratio Change

RAMAT GAN, ISRAEL, March 20, 2026 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]